Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Arginase deficiency is a rare autosomal recessive metabolic disorder that disrupts the final step of the urea cycle, impairing the conversion of arginine into urea and ornithine. In affected ...

Investing.com -- Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) stock rose 2% following positive interim results from two Phase 2 clinical trials of its ARCT-810 mRNA therapeutic for ornithine ...

A faulty lab test report that triggers panic and emergency hospitalisation amounts to a deficiency in service, Delhi State ...

The National Urea Cycle Disorders Foundation, the leading patient advocacy group for people affected by urea cycle disorders ...

The Delhi State Consumer Disputes Redressal Commission has upheld a ruling against Dr Lal Pathlabs for negligence in ...

We spoke with the developers and manufacturers of the CRISPR gene therapy used to treat KJ Muldoon’s rare genetic condition, ...

Researchers with the Urea Cycle Disorders Consortium (UCDC) are among those who will join the project. NUCDF is the sole patient advocacy partner for this expert research network, which was funded ...

Last month, a baby got the world’s first personalized gene-editing treatment. What will this mean for millions of others with ...